AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10637204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of carbachol
Number of subjects: 24
Study 10637204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of L-NMMA
Number of subjects: 24
Study 10637204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of carbachol followed by coinfusion with L-NMMA
Number of subjects: 24
Study 9314339 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (ragweed immunotherapy)
Number of subjects: 20
Study 9314339 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 9314339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (initial immunotherapy)
Number of subjects: 20
Study 9314339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (symptom diaries)
Number of subjects: 20
Study 7680641 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention (supplemental in-hospital education followed by telephone contact from discharge to eighth week after discharge)
Number of subjects: 156
Study 7680641 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 156
Study 3954126 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 20
Study 3954126 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study 29658831 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-burst interval locomotor treadmill training (SBLTT)
Number of subjects: 12
Study 28257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 43
Study 28257614 — intervention group
Group type: COMPARATOR
Intervention: Cortisone Injection
Number of subjects: 43
Study 28257614 — intervention group
Group type: COMPARATOR
Intervention: Medication intake for pain
Number of subjects: 43
Study 25361981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ER receptor signaling and apoptosis gene module scores
Number of subjects: 111
Study 25361981 — intervention group
Group type: EXPERIMENTAL
Intervention: High AKT-MTOR, Ras, and β-catenin module scores
Number of subjects: 111
Study 25361981 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-like subtype
Number of subjects: 111
Study 25361981 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-enriched subtype
Number of subjects: 111
Study 25361981 — intervention group
Group type: COMPARATOR
Intervention: Luminal A subtype
Number of subjects: 111
Study 25361981 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall distribution of subtypes
Number of subjects: 111
Study 24289059 — intervention group
Group type: EXPERIMENTAL
Intervention: New Medicine Service (NMS) intervention comprising pharmacist-delivered support for a newly prescribed medicine
Number of subjects: 250
Study 24289059 — intervention group
Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 250
Study 21828126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (HD-DN, 90 mg/m² per day times 3 days)
Number of subjects: 383
Study 21828126 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose daunorubicin (SD-DN, 45 mg/m² per day times 3 days)
Number of subjects: 383
Study 21828126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (HD-DN)
Number of subjects: 383
Study 21828126 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose daunorubicin (SD-DN)
Number of subjects: 383
Study 19214363 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the PFIQ
Number of subjects: 44
Study 19214363 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the PFDI
Number of subjects: 44
Study 19214363 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of both questionnaires
Number of subjects: 44
Study 16674198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical model applied to in vivo fluorescence measurements
Number of subjects: 292
Study 15116990 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding-speeded response (ESR) paradigm
Number of subjects: 0
Study 15116990 — intervention group
Group type: COMPARATOR
Intervention: Psychological refractory period (PRP) paradigm
Number of subjects: 0
Study 11417033 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary sodium stibogluconate (Pentostam, PSM)
Number of subjects: 102
Study 11417033 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic sodium stibogluconate (SSG)
Number of subjects: 102
Study 11417033 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 102
Study 9340641 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.5 ml per kg of body weight of 80 proof vodka)
Number of subjects: 10
Study 9340641 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 10
Study 9340641 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP pressure determination by AutoSet
Number of subjects: 10
Study 8343351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue applied intraoperatively
Number of subjects: 24
Study 8343351 — intervention group
Group type: COMPARATOR
Intervention: No complementary treatment (Control)
Number of subjects: 24
Study 3739798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehearsal (Self‐instructional training)
Number of subjects: 94
Study 3739798 — intervention group
Group type: COMPARATOR
Intervention: Insight Control
Number of subjects: 94
Study 3739798 — intervention group
Group type: COMPARATOR
Intervention: Individual Contact Control
Number of subjects: 94
Study 3739798 — intervention group
Group type: COMPARATOR
Intervention: Group Contact Control (core programme only)
Number of subjects: 94
Study 3739798 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 94
Study 3739798 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial weight loss
Number of subjects: 94
Study 28976265 — intervention group
Group type: COMPARATOR
Intervention: Gr.Suppl.0 (control group) - no supplementation
Number of subjects: 133
Study 28976265 — intervention group
Group type: EXPERIMENTAL
Intervention: Gr.Suppl.5 - 5 µg daily dose of VitD3-fortified yogurt
Number of subjects: 133
Study 28976265 — intervention group
Group type: EXPERIMENTAL
Intervention: Gr.Suppl.10 - 10 µg daily dose of VitD3-fortified yogurt
Number of subjects: 133
Study 27133029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanicemine
Number of subjects: 60
Study 27133029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 60
Study 27133029 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 24825853 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG screening (experimental group)
Number of subjects: 952
Study 24825853 — intervention group
Group type: EXPERIMENTAL
Intervention: False-positive results (experimental group)
Number of subjects: 952
Study 24825853 — intervention group
Group type: COMPARATOR
Intervention: Standardised history and physical examination (control group)
Number of subjects: 952
Study 22301333 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition group (monetary reward for pain task trials performed)
Number of subjects: 56
Study 22301333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no competing goal)
Number of subjects: 56
Study 22301333 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition group
Number of subjects: 56
Study 22301333 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 20487638 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest physiotherapy (MCP)
Number of subjects: 526
Study 20487638 — intervention group
Group type: COMPARATOR
Intervention: No MCP (Control)
Number of subjects: 526
Study 18395907 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepacol (sodium phosphate and bisacodyl) preparation in 26 patients
Number of subjects: 52
Study 18395907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Prepacol preparation) in 26 patients
Number of subjects: 52
Study 15562015 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (500 mg twice daily with meals)
Number of subjects: 52
Study 15562015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11953691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 73
Study 11953691 — intervention group
Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 73
Study 9798657 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Group A, n = 11)
Number of subjects: 18
Study 9798657 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C, n = 36)
Number of subjects: 18
Study 9798657 — intervention group
Group type: EXPERIMENTAL
Intervention: Total SS group (Groups A and B)
Number of subjects: 18
Study 8559945 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine with additional psychotherapy
Number of subjects: 50
Study 8559945 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin with additional psychotherapy
Number of subjects: 50
Study 8559945 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 2677292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutramigen
Number of subjects: 17
Study 2677292 — intervention group
Group type: COMPARATOR
Intervention: Cow milk
Number of subjects: 17
Study 869086 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking withdrawal clinic protocols (various drugs and education methods)
Number of subjects: 800
Study 869086 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and psychological characteristics
Number of subjects: 800
Study 31676157 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual hand sanitizer (quaternary ammonium‐based)
Number of subjects: 0
Study 31676157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresidual hand sanitizer (60% ethanol)
Number of subjects: 0
Study 30959006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.2 mg/kg (group MD)
Number of subjects: 90
Study 30959006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin 0.4 mg/kg (group M)
Number of subjects: 90
Study 30959006 — intervention group
Group type: COMPARATOR
Intervention: Oral multivitamin tablet as placebo (group P)
Number of subjects: 90
Study 29336763 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily chlorhexidine gluconate (CHG) baths and mupirocin (MUP) ointment to the nares
Number of subjects: 92
Study 29336763 — intervention group
Group type: COMPARATOR
Intervention: Soap and water baths and placebo ointment
Number of subjects: 92
Study 25707404 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing
Number of subjects: 20
Study 25707404 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 20
Study 24517052 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XC) 3 tablets thrice daily for 12 weeks
Number of subjects: 80
Study 24517052 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine anti‐rheumatic treatment: Methotrexate 10 mg/week; Diclofenac 50 mg twice daily when pain was obvious)
Number of subjects: 80
Study 20713434 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-exercise training
Number of subjects: 16
Study 20713434 — intervention group
Group type: COMPARATOR
Intervention: Resistance-exercise training
Number of subjects: 16
Study 19558302 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp clips (Scalpfix, Aesculap)
Number of subjects: 150
Study 19558302 — intervention group
Group type: COMPARATOR
Intervention: Artery forceps
Number of subjects: 150
Study 19558302 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of operation
Number of subjects: 150
Study 16638738 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (rivaroxaban) 5 mg tablets (fasted and fed)
Number of subjects: 0
Study 16638738 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (rivaroxaban) 10 mg
Number of subjects: 0
Study 16638738 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (rivaroxaban) 20 mg
Number of subjects: 0
Study 16638738 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (rivaroxaban) with food
Number of subjects: 0
Study 16638738 — intervention group
Group type: COMPARATOR
Intervention: BAY 59-7939 (rivaroxaban) with ranitidine (150 mg twice daily)
Number of subjects: 0
Study 16638738 — intervention group
Group type: COMPARATOR
Intervention: BAY 59-7939 (rivaroxaban) with antacid (10 mL)
Number of subjects: 0
Study 15598997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - initial conservative treatment followed by interval appendectomy six weeks later
Number of subjects: 60
Study 15598997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - appendectomy as soon as appendiceal mass resolved using conservative means
Number of subjects: 60
Study 15598997 — intervention group
Group type: COMPARATOR
Intervention: Group C - conservative treatment alone
Number of subjects: 60
Study 11739971 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without border zone infarcts (n=26)
Number of subjects: 51
Study 11739971 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with border zone infarcts (n=25)
Number of subjects: 51
Study 11739971 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral flow via the posterior communicating artery
Number of subjects: 51
Study 11739971 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients with ICA occlusion
Number of subjects: 51
Study 11739971 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 9709410 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (2-8 pmol/min)
Number of subjects: 8
Study 9709410 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (2-8 pmol/min) with L-NMMA (1-4 micrograms/min)
Number of subjects: 8
Study 9709410 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (1-4 micrograms/min) alone
Number of subjects: 8
Study 8037263 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine
Number of subjects: 14
Study 8037263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2919798 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium metabisulfite oral aqueous challenge
Number of subjects: 13
Study 2919798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 5440547 — intervention group
Group type: EXPERIMENTAL
Intervention: External pressure between 5 and 15 mm. Hg
Number of subjects: 9
Study 5440547 — intervention group
Group type: EXPERIMENTAL
Intervention: External pressure above 15 mm. Hg
Number of subjects: 9
Study 30520405 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 351
Study 30520405 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 351
Study 30520405 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care stigma
Number of subjects: 351
Study 29718430 — intervention group
Group type: EXPERIMENTAL
Intervention: +LPS
Number of subjects: 20
Study 29718430 — intervention group
Group type: EXPERIMENTAL
Intervention: +BCAA
Number of subjects: 20
Study 26897454 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention (HLI)
Number of subjects: 160
Study 26897454 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 160
Study 25252600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 240
Study 25252600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 240
Study 25252600 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI (Control)
Number of subjects: 240
Study 25252600 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Bivalirudin anticoagulation and thrombus aspiration)
Number of subjects: 240
Study 22805498 — intervention group
Group type: EXPERIMENTAL
Intervention: 250,000 IU of cholecalciferol
Number of subjects: 30
Study 22805498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21061834 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg/day)
Number of subjects: 34
Study 21061834 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (300 mg/day)
Number of subjects: 34
Study 17376712 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 98
Study 17376712 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 98
Study 17376712 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 98
Study 17376712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.14% calcium hydroxide
Number of subjects: 98
Study 17376712 — intervention group
Group type: EXPERIMENTAL
Intervention: polymyxin B
Number of subjects: 98
Study 17376712 — intervention group
Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 98
Study 17376712 — intervention group
Group type: COMPARATOR
Intervention: negative control (no endotoxin)
Number of subjects: 98
Study 16329464 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-9,trans-11 CLA (3 g/day)
Number of subjects: 42
Study 16329464 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-10,cis-12 CLA (3 g/day)
Number of subjects: 42
Study 16329464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturia (mean of twice or more/night)
Number of subjects: 4721
Study 12410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, poor health status, and use of medication
Number of subjects: 4721
Study 12410740 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' routine checks
Number of subjects: 4721
Study 10421262 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy at a total dose of 60 gray
Number of subjects: 728
Study 10421262 — intervention group
Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 728
Study 10421262 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 728
Study 7669462 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block with 0.5% bupivacaine and adrenaline 1/200,000 40 ml with the addition of morphine 5 mg
Number of subjects: 40
Study 7669462 — intervention group
Group type: COMPARATOR
Intervention: Interscalene brachial plexus block with 0.5% bupivacaine and adrenaline 1/200,000 40 ml alone
Number of subjects: 40
Study 2401752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg) administered after food
Number of subjects: 0
Study 2401752 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (250 mg) administered after antacid
Number of subjects: 0
Study 2401752 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (250 mg) administered in fasting conditions
Number of subjects: 0
Study 7434079 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinacrine (100 mg t.i.d. for 5 days)
Number of subjects: 124
Study 7434079 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (200 mg t.i.d. for 7 days)
Number of subjects: 124
Study 7434079 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (2 gm single dose)
Number of subjects: 124
Study 7434079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 gm single dose)
Number of subjects: 124
Study 7434079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole (2 gm single dose)
Number of subjects: 124
Study 7434079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 6134959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg IM
Number of subjects: 117
Study 6134959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg IM
Number of subjects: 117
Study 6134959 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin 2 g IM
Number of subjects: 117
Study 6134959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 117
Study 6134959 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 117
Study 31059947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hisense computer-assisted surgery (CAS) system
Number of subjects: 104
Study 31059947 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT) group
Number of subjects: 104
Study 29293361 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 80
Study 29293361 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 80
Study 26597368 — intervention group
Group type: EXPERIMENTAL
Intervention: PHP‐Mel
Number of subjects: 93
Study 26597368 — intervention group
Group type: COMPARATOR
Intervention: BAC
Number of subjects: 93
Study 23639952 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy (12 sessions, two 30-min sessions per week for 6 weeks)
Number of subjects: 104
Study 23639952 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy
Number of subjects: 104
Study 23639952 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 22495183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/70 kg
Number of subjects: 10
Study 22495183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg/70 kg
Number of subjects: 10
Study 22495183 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (daily administration)
Number of subjects: 10
Study 22495183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (intermittent administration)
Number of subjects: 10
Study 22495183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily administration)
Number of subjects: 10
Study 19793397 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate retaining total knee arthroplasty
Number of subjects: 0
Study 19793397 — intervention group
Group type: COMPARATOR
Intervention: Posterior stabilized total knee arthroplasty
Number of subjects: 0
Study 19793397 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured by SF-36
Number of subjects: 0
Study 19793397 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reported functional status and range of motion measured by Knee Society Clinical Rating System (KSS)
Number of subjects: 0
Study 17984150 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical activity
Number of subjects: 29